人工智能对结直肠肿瘤漏诊率的影响
在这项多中心随机对照试验中,230例接受结直肠癌筛查或监测的患者被1:1随机分配至先行人工智能结肠镜或先行标准结肠镜,随后同日行第二次结肠镜检查。人工智能组腺瘤漏诊率显著低于标准结肠镜组(15.5% vs 32.4%,调整OR 0.38,95%CI 0.23-0.62),假阴性率亦降低,不良事件率无差异。
要点
- 人工智能结肠镜使结直肠肿瘤漏诊率降低约2倍(调整OR 0.38,95%CI 0.23-0.62)。
- ≤5 mm病变漏诊率AI组15.9% vs 标准组35.8%,非息肉样病变16.8% vs 45.8%。
- 两组不良事件发生率无差异。
核心结论
- 人工智能使结直肠肿瘤漏诊率降低约2倍,支持人工智能在标准结肠镜检查中减少对小而隐匿病变的感知错误。
研究设计与样本
- 多中心(意大利、英国、美国8个中心)随机对照试验,纳入接受结直肠癌筛查或监测的患者230例,1:1随机分配至先行人工智能结肠镜或先行标准结肠镜,同日行两次背靠背结肠镜检查。
主要发现
- 总体腺瘤漏诊率AI组为15.5%(38/246),标准结肠镜组为32.4%(80/247),调整OR 0.38(95%CI 0.23-0.62)。
- ≤5 mm病变漏诊率AI组15.9% vs 标准组35.8%(OR 0.34,95%CI 0.21-0.55);非息肉样病变16.8% vs 45.8%(OR 0.24,95%CI 0.13-0.43)。
- 近端结肠漏诊率AI组18.3% vs 标准组32.5%(OR 0.46,95%CI 0.26-0.78);远端结肠10.8% vs 32.1%(OR 0.25,95%CI 0.11-0.57)。
- 第二次结肠镜平均腺瘤数AI组0.33±0.63 vs 标准组0.70±0.97(P<.001)。
- 假阴性率AI组6.8%(3/44)vs 标准组29.6%(13/44),OR 0.17(95%CI 0.05-0.67);两组不良事件发生率无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Artificial intelligence (AI) may detect colorectal polyps that have been missed due to perceptual pitfalls. By reducing such miss rate, AI may increase the detection of colorectal neoplasia leading to a higher degree of colorectal cancer (CRC) prevention. METHODS: Patients undergoing CRC screening or surveillance were enrolled in 8 centers (Italy, UK, US), and randomized (1:1) to undergo 2 same-day, back-to-back colonoscopies with or without AI (deep learning computer aided diagnosis endoscopy) in 2 different arms, namely AI followed by colonoscopy without AI or vice-versa. Adenoma miss rate (AMR) was calculated as the number of histologically verified lesions detected at second colonoscopy divided by the total number of lesions detected at first and second colonoscopy. Mean number of lesions detected in the second colonoscopy and proportion of false negative subjects (no lesion at first colonoscopy and at least 1 at second) were calculated. Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted by endoscopist, age, sex, and indication for colonoscopy. Adverse events were also measured. RESULTS: A total of 230 subjects (116 AI first, 114 standard colonoscopy first) were included in the study analysis. AMR was 15.5% (38 of 246) and 32.4% (80 of 247) in the arm with AI and non-AI colonoscopy first, respectively (adjusted OR, 0.38; 95% CI, 0.23-0.62). In detail, AMR was lower for AI first for the ≤5 mm (15.9% vs 35.8%; OR, 0.34; 95% CI, 0.21-0.55) and nonpolypoid lesions (16.8% vs 45.8%; OR, 0.24; 95% CI, 0.13-0.43), and it was lower both in the proximal (18.3% vs 32.5%; OR, 0.46; 95% CI, 0.26-0.78) and distal colon (10.8% vs 32.1%; OR, 0.25; 95% CI, 0.11-0.57). Mean number of adenomas at second colonoscopy was lower in the AI-first group as compared with non-AI colonoscopy first (0.33 ± 0.63 vs 0.70 ± 0.97, P < .001). False negative rates were 6.8% (3 of 44 patients) and 29.6% (13 of 44) in the AI and non-AI first arms, respectively (OR, 0.17; 95% CI, 0.05-0.67). No difference in the rate of adverse events was found between the 2 groups. CONCLUSIONS: AI resulted in an approximately 2-fold reduction in miss rate of colorectal neoplasia, supporting AI-benefit in reducing perceptual errors for small and subtle lesions at standard colonoscopy. CLINICALTRIALS: gov, Number: NCT03954548.
引用
- Wallace MB, Sharma P, Bhandari P, et al. Impact of Artificial Intelligence on Miss Rate of Colorectal Neoplasia. Gastroenterology. 2022. PMID: 35304117. doi:10.1053/j.gastro.2022.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。